(Q34204376)

31 July 2017

1 reference

title

Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management (English)

1 reference

31 July 2017

Cantor LB

1

1 reference

PubMed ID

11281821

31 July 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

1 reference

31 July 2017

10

1 reference

31 July 2017

4

1 reference

31 July 2017

721-731

1 reference

Neuronal death in glaucoma

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

TUNEL-positive ganglion cells in human primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

Intraocular pressure-dependent progression of visual field loss in advanced primary open-angle glaucoma: a 15-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

Intraocular pressure and progression of glaucomatous visual field loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

Changing therapeutic paradigms in glaucoma management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

Target pressure--glaucomatologists' holey grail.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

Medical treatment of glaucoma--a reappraisal of the risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

Glaucoma medical treatment: philosophy, principles and practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

Clinical experience with latanoprost: a retrospective study of 153 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

Replacement of the carboxylic acid group of prostaglandin f(2alpha) with a hydroxyl or methoxy substituent provides biologically unique compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.4.721

10.1517/13543784.10.4.721

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11281821